Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Actelion partners with PatientsLikeMe on blood cancer research

Will create patient-reported outcomes tool for rare form of non-Hodgkin’s lymphoma
PatientsLikeMe Open Research Exchange ORE

Actelion has formed a research partnership with an online patient community to create a new research tool for a rare form of non-Hodgkin's lymphoma.

The Swiss pharma company and PatientsLikeMe will work with patients to develop new health measures that better reflect patients' experiences living with and managing MF-CTCL., a disfiguring cancer, primarily of the skin.

The most prevalent form of cutaneous T-cell lymphomas (CTCL), mycosis fungoides CTCL accounts for about two per cent of all lymphomas.

Mitchell Nagao, Actelion's senior director - medical head of Valchlor and Zavesca, said: “As changes in technology, culture, and treatment affect how patients live with disease, we want measurement to evolve accordingly.

“Our work with PatientsLikeMe will help ensure we're applying the best principles for patient-centered research and giving tools back to the community so they can evolve them even more.”

Actelion joins the likes of Sanofi, Merck & Co and Boehringer Ingelheim in working with PatientsLikeMe, but will be the first pharma company to use its online Open Research Exchange (ORE) hub.

PatientsLikeMe vice president of innovation Paul Wicks: “We created ORE to help patients and researchers work together to transform care and discovery that truly serve the patient. Now we're past the initial pilot stage, and it's exciting to see members of industry engaging with patients to develop more tools that really measure what matters to patients.”

6th August 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...